Global study shows rotavirus vaccine cuts deaths from gastroenteritis by 76%

A large-scale study recently featured in The Lancet Child & Adolescent Health has found that even a single dose of the rotavirus vaccine can reduce mortality from rotavirus-positive acute gastroenteritis by 75.8%. Looking at data from 27,252 children under five years old across 22 countries, researchers determined that those who were vaccinated were nearly 14 times less likely to die from the condition than their unvaccinated counterparts. These results highlight how vital vaccination remains for children, especially in areas where rotavirus is common.

The analysis drew on pooled data from the Multi-National Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V), covering 24 countries between July 2007 and August 2023. While the vaccine significantly lowered deaths specifically tied to rotavirus-positive gastroenteritis, its impact on overall deaths from all forms of acute gastroenteritis was not statistically significant. Among the 16 countries that reported fatalities, there were 183 deaths from all-cause acute gastroenteritis and 25 specifically caused by rotavirus.

Significant gaps in vaccination coverage appeared between urban and rural areas. Children treated in rural hospitals were often nearly twice as likely to be unvaccinated as those in cities. Most rotavirus-related deaths occurred in African countries, pointing to a pressing need for better healthcare infrastructure and vaccine access. The study also noted that deaths were more frequent among children who lacked both timely rehydration therapy and vaccination, suggesting that both prevention and treatment measures are falling short in some regions.

These findings carry weight for public health policy and practice. Researchers argue that prioritizing timely vaccination and strengthening health systems are essential steps toward lowering mortality rates for children at risk. The data indicates that broader vaccination coverage may also offer indirect protection to children with chronic health issues, who face a higher risk of death from diarrhea. This supports the case for broader strategies that include investment in nutrition, sanitation, and healthcare to bolster child health alongside immunization.

This research arrives as the U.S. shifts its own stance on the vaccine. A recent executive order reclassified the rotavirus vaccine from a universal recommendation to a “shared clinical decision-making” approach, a change that could influence future vaccination rates. The study offers clear evidence for the continued use of the vaccine as a primary tool to reduce child mortality from gastroenteritis. Ensuring equitable access and closing the gaps in coverage will be essential to reducing these preventable deaths on a global scale.